Fig. 4: Infectivity of the spike(D796H, ΔH69/ΔV70) variant and sensitivity to convalescent plasma treatment.
From: SARS-CoV-2 evolution during treatment of chronic infection
a, Western blot of virus pellets after centrifugation of supernatants from cells transfected with lentiviral pseudotyping plasmids that included the spike protein. Blots are representative of two independent transfections. b, Single-round infectivity of luciferase-expressing lentiviruses pseudotyped with the spike protein (wild-type (WT) or mutant) of SARS-CoV-2 in HEK293T cells co-transfected with ACE2 and TMPRSS2 plasmids. Infectivity is corrected for reverse transcriptase activity in the virus supernatant as measured by qPCR. Data points represent technical replicates (n = 3). Data are mean ± s.e.m. of two independent experiments. RLU, relative light units; nU, nanounit. c–e, Neutralization potency of convalescent plasma units (CP1–CP3) against pseudotyped viruses bearing spike(D796H), spike(ΔH69/ΔV70) and spike(D796H, ΔH69/ΔV70). f, g, Neutralizing potency of the serum of patient X1 against pseudotyped virus bearing spike(D796H), spike(ΔH69/ΔV70) and spike(D796H, ΔH69/ΔV70). Patient serum was taken on the indicated days. The serum dilution required to inhibit 50% of virus infection (ID50) is shown, expressed as a fold change relative to the wild-type virus. Data points represent means of technical replicates (horizontal bars) obtained an independent experiments (n = 2–6).
